UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Novartis

N

Novartis

Cardiovascular & MetabolicBasel, Switzerland
Visit Website

About Novartis

Novartis ranks among the world's largest pharmaceutical companies, built on the 1996 merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical giants with roots stretching back to the nineteenth century. Headquartered in Basel, Switzerland, the company operates across more than 100 countries and employs hundreds of thousands of people globally, making it one of the defining organisations in modern medicine.

Innovative Medicines

The core innovative medicines division focuses on developing and commercialising patented treatments across a concentrated set of therapeutic areas. Oncology is a particular strength, with the company having established early leadership in targeted cancer therapies, including kinase inhibitors that reshaped haematology. Cardiovascular, immunology, neuroscience, and ophthalmology round out the primary focus areas. The company's cell and gene therapy ambitions are embodied in platforms that have drawn significant industry attention, positioning Novartis at the frontier of advanced therapeutic modalities.

Sandoz & the Generics Legacy

For much of its post-merger history, Novartis operated a substantial generics and biosimilars business under the Sandoz brand. In 2023, Sandoz was spun off as an independent publicly traded company, sharpening Novartis's focus entirely on patented innovative medicines. The separation reflected a broader strategic decision to concentrate resources where the company sees its strongest long-term competitive position.

Novartis is listed on the SIX Swiss Exchange under the ticker NOVN and on the New York Stock Exchange as NVS, giving it access to deep capital markets to fund its substantial research and development programme. The company consistently ranks among the top spenders on pharmaceutical R&D globally, operating research facilities across Europe, North America, and Asia.

Radioligand therapy represents one of the newer strategic bets, combining targeted delivery mechanisms with therapeutic isotopes, an area Novartis has pursued through acquisitions and internal development. The company's commercial pipeline and approved portfolio span small molecules, biologics, and cell-based therapies, reflecting the breadth of its scientific capabilities.

Further information is available at novartis.com.

Similar Companies

More in Cardiovascular & Metabolic

G

GE HealthCare

GE HealthCare spun out of General Electric in January 2023 to become an independent, publicly traded medical technology company, bringing with it more than a century of imaging and diagnostics heritage. Listed on the Nasdaq under the ticker GEHC, the company operates across more than 160 countries, serving hospitals, imaging centres, and life-science laboratories worldwide. Imaging & Diagnostics Portfolio The company's core business centres on medical imaging systems, including MRI, CT, PET/CT, X-ray, and ultrasound platforms. Its portfolio spans everything from point-of-care ultrasound devices to large-bore scanners used in oncology and cardiology departments. GE HealthCare's Edison platform provides an open software ecosystem that allows AI-powered applications to be deployed directly on imaging hardware, enabling faster interpretation and workflow automation at the point of care. Patient Care Solutions & Pharmaceutical Diagnostics Beyond capital equipment, GE HealthCare supplies pharmaceutical diagnostics (contrast agents and radiopharmaceutical tracers), patient monitoring systems, and anaesthesia delivery products. Its pharmaceutical diagnostics division manufactures contrast media used in MRI and CT procedures globally, making it one of the largest producers in that segment. The company also provides service contracts, digital health software, and data analytics tools designed to improve operational efficiency in clinical environments. Headquartered in Chicago, Illinois, GE HealthCare employs tens of thousands of people worldwide and maintains manufacturing and research facilities across North America, Europe, and Asia-Pacific. Its customer base includes academic medical centres, community hospitals, outpatient imaging networks, and pharmaceutical manufacturers conducting clinical research. The company organises its business into four reporting segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting the breadth of its involvement across the care pathway from diagnosis through monitoring. Strategic priorities since independence have included expanding AI-enabled software revenue, growing its services business, and extending its presence in emerging markets. Further information is available at gehealthcare.com.

View profile
F

Fortrea

Spun out of Labcorp in 2023, Fortrea entered the contract research organisation market as an independent company with decades of accumulated trial execution expertise behind it. Headquartered in Durham, North Carolina, the organisation operates across more than 90 countries and employs tens of thousands of staff, making it one of the larger CROs active globally from the moment of its launch. Fortrea's core offering centres on clinical development services, spanning Phase I through Phase IV trials across a broad range of therapeutic categories. The company provides site management, patient recruitment, data management, bioanalytical laboratory services, and regulatory affairs support, giving sponsors a largely integrated pathway from early-phase work through post-market studies. Alongside its clinical operations, Fortrea runs an enabling services division that handles functional service provider arrangements, allowing biopharmaceutical clients to access specific capabilities without committing to a full-service model. This flexibility is particularly valued by mid-size and emerging biotechnology sponsors managing constrained timelines and budgets. The company is publicly listed on the Nasdaq stock exchange under the ticker FTRE. Its client base spans large multinational pharmaceutical companies, specialist biotechnology firms, and medical device developers, with therapeutic depth in oncology, central nervous system disorders, infectious disease, cardiovascular medicine, and immunology. Further information is available at fortrea.com.

View profile
W

Worldwide Clinical Trials

Operating across more than 60 countries, Worldwide Clinical Trials is a full-service contract research organisation built around a single discipline: clinical development. Founded in 1986, the company has spent nearly four decades focusing exclusively on Phase I through Phase IV studies, giving it a depth of therapeutic and regulatory expertise that generalist CROs rarely match. The organisation is particularly well regarded for its work in central nervous system research, where it operates dedicated CNS units with specialist investigators and patient populations. Alongside CNS, Worldwide Clinical Trials carries strong capabilities in cardiovascular, metabolic, and rare disease development, areas where patient recruitment complexity and protocol design demand experienced hands. Its Phase I infrastructure includes purpose-built clinical pharmacology units that support first-in-human studies, bioavailability and bioequivalence work, and early proof-of-concept programmes. This early-phase foundation connects seamlessly into its late-phase trial management, allowing sponsors to maintain a single CRO relationship from initial dosing through to regulatory submission. Worldwide Clinical Trials works primarily with mid-size and emerging biopharmaceutical companies, positioning itself as a committed partner rather than a high-volume processor. That focus has earned it a reputation for therapeutic expertise and operational flexibility, qualities that sponsors managing complex or novel compounds tend to prioritise. Headquarters are in Wayne, Pennsylvania, with a global network of offices and clinical sites spanning North America, Europe, and beyond. Further information is available at worldwide.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy